Jade Biosciences, Inc. (NASDAQ:JBIO) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts give Jade Biosciences an average rating of Moderate Buy across nine firms (2 sell, 5 buy, 2 strong buy) with a consensus 12‑month price target of $29.50.
• Institutional interest picked up in Q2, with new stakes established by several firms — led by Geode Capital Management (~$6.76M) and including Intech, JPMorgan, Rhumbline and Legal & General.
• Shares opened at $16.02 (market cap ≈ $790M) and trade within a 52‑week range of $6.57–$100.10; the company reported Q1 EPS of ($0.11), beating the ($0.45) consensus.

Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) has earned an average rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $29.50.

JBIO has been the subject of a number of research analyst reports. Weiss Ratings reiterated a "sell (e+)" rating on shares of Jade Biosciences in a research report on Monday, December 29th. Wedbush reiterated an "outperform" rating and set a $24.00 price objective on shares of Jade Biosciences in a report on Monday, March 9th. HC Wainwright lifted their price objective on Jade Biosciences from $25.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday, March 25th. William Blair upgraded Jade Biosciences to a "strong-buy" rating in a research note on Monday, March 9th. Finally, Lifesci Capital raised Jade Biosciences to a "strong-buy" rating in a research report on Friday, March 6th.

Institutional Investors Weigh In On Jade Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC acquired a new stake in shares of Jade Biosciences in the second quarter worth about $6,759,000. Intech Investment Management LLC bought a new position in Jade Biosciences in the 2nd quarter worth approximately $230,000. JPMorgan Chase & Co. bought a new position in Jade Biosciences during the second quarter worth $154,000. Legal & General Group Plc acquired a new position in shares of Jade Biosciences during the second quarter valued at about $29,000. Finally, Rhumbline Advisers bought a new position in Jade Biosciences during the second quarter valued at about $445,000.

Jade Biosciences Price Performance

Shares of JBIO opened at $16.02 on Thursday. The business's 50-day moving average is $14.62 and its 200-day moving average is $12.71. The company has a market capitalization of $790.11 million, a price-to-earnings ratio of -3.48 and a beta of 1.03. Jade Biosciences has a fifty-two week low of $6.57 and a fifty-two week high of $100.10.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last posted its quarterly earnings results on Friday, March 6th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.34.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.